Frequently Asked Questions for RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, & RFA-RM-17-028

The following Frequently Asked Questions (FAQs) are for Use-Inspired Research to Optimize Adherence, Behavior Change Interventions, and Outcomes competing revision (R01, U01, R34) and exploratory/developmental (R21) funding opportunity announcements (RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, & RFA-RM-17-028). For additional background on the SOBC Research Network please see the original FAQs.

SOBC Measures Repository Questions

1. Will more measures be added to the repository by the December application deadline, particularly for the interpersonal and social processes and stress reactivity and stress resilience domains?

2. The FOAs require use of at least one measure or assay from the SOBC Measures Repository. Can additional measures be used in conjunction with these?

3. What internet browser should I use to access the SOBC Measures Repository?

Competing Revision Questions

4. Are revision applications limited to adding measures, or may they propose an additional intervention arm?

5. Can the parent award be from any of Institute or Center?

6. For these applications is “clinical trial” defined using the newer, broad definition from the NIH NOT-OD-15-015?

7. Can the Principal Investigator (PI) for the competing revision application be a different person than the parent award PI?

8. Would the competing revision award start-up date have to coincide with the parent award timeline?

9. Can we apply for the competing revision if the clinical trial grant has not yet been awarded?

10. Is there a relative preference for studies that include experimental manipulation in a new arm versus studies that use multiple measures from the repository and statistical methods to uncover potentially multiple mechanisms?

R21 Questions

11. Should the focus in R21 applications always on patient-oriented outcomes (e.g., medication adherence), or could the behavior change also be focused on provider behaviors (e.g., medication ordering behaviors)?

12. How many health behavior outcomes are needed for the R21? If the proposed study includes multiple measures of medication adherence, is another health behavior needed?

13. Can we speak with one of the scientific contacts about general questions (e.g., regarding the R21 activity code) without having a specific aims page ready yet?

14. I noticed that the FOAs were advertised by NIDA and NCI. Is the R21 required to be fundable by NIDA or NCI or could it be targeted to another Institute or Center depending on the outcome of interest?

15. Do you know how many R21s will be funded?

16. Should we propose a clinical trial study as part of an R21 application?

17. Why is the R21 deadline December 5, 2017 when the standard cycle 1 due date for new R21s at NIH is February 16, 2018?

18. For the R21 are interventions based on technologies like smartphones of interest?

General Questions

19. What types of activities are anticipated for these RFAs and are there any relative priorities? Specifically, is there priority for assay development and refinement versus target engagement studies versus broader longitudinal studies that include both demonstrations of target engagement and behavior change?

20. Is the Letter of Intent required?

21. Are we obligated to submit an application if we submit a Letter of Intent?

22. What information is needed in the Letter of Intent and how should we submit it?

23. Are international sites supported?

24. When will successful grants be awarded?

25. What are some example targets for treatment (medical regimen) adherence?

26. Are there sample applications for these opportunities available to view?

 

This page last reviewed on November 8, 2017